Shuli Qu

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 3

Top Topics

Randomized Controlled Trial

Top Venues

Expert review of pharmacoeconomics & outcomes research

Future oncology (London, England)

IQVIA

This page only lists publications with an associated author ORCID identifier.

Affiliation History

IQVIA Dec 01 2015

United States

Sr. Consultant :: RWI

Publications

Lei Zhang, Yijiao Qian, Jinnan Li, Chenwei Cui, Lu Chen, Shuli Qu, Shun Lu
Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer. Future oncology (London, England) 18 (15) (2022)
Zhan-Miao Yi, Peng Men, Shuli Qu, Chaoyun Li, Xin Yu, Suodi Zhai
Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China. Expert review of pharmacoeconomics & outcomes research 20 (3) (2020)
Jiujie Cui, Xiaochen Zhang, Shuli Qu, Liwei Wang
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china. Expert review of pharmacoeconomics & outcomes research 21 (4) (2020)